View Post

Dengue Vaccine Candidate Seeks Europe’s Approval

In COVID-19, Latest News by Precision Vaccinations

The European Medicines Agency (EMA) has accepted Takeda Pharmaceutical Company Limited’s filing packages for its dengue vaccine candidate (TAK-003), which is being investigated to prevent dengue due to any dengue virus serotype in individuals ages four to 60.
Dengue is the fastest spreading mosquito-borne viral disease and was one of the World Health Organization’s leading global health risks in 2019. Dengue is estimated to cause 390 million infections and around 20,000 fatalities globally each year.